James S Blachly
Ohio State University Comprehensive Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name James S Blachly as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:18 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03724084 · Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene RearrangementNational Cancer Institute (NCI) · terminated · Acute Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials NetworkUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON, Narendranath Epperla · fiscal years 2014 to 2026Named on NCT03724084
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:18 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).J Clin Oncol · 2025236 citationsRCR 60.4
- Expression and prognostic impact of lncRNAs in acute myeloid leukemia.Proc Natl Acad Sci U S A · 2014205 citationsRCR 5.5
- 79 citationsRCR 18.7
- A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies.Clin Cancer Res · 202455 citationsRCR 6.6
- Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study.Leuk Lymphoma · 202037 citationsRCR 1.6
- Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression.Clin Cancer Res · 202037 citationsRCR 1.4
- A precision medicine classification for treatment of acute myeloid leukemia in older patients.J Hematol Oncol · 202113 citationsRCR 0.7
- Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.Leuk Lymphoma · 202313 citationsRCR 1.3
- 4 citationsRCR 0.2